Kinect - HD: NOW RECRUITNG
We are participating in a new study of a treatment for chorea associated with Huntington's disease. The study is of a medication called Valbenazine to treat chorea, and is being conducted by the Huntington Study Group and Neurocrine Biosciences. The study involves 9 visits and will last 18 weeks. There is the opportunity to stay on the drug after the first part of the study is over. Participants will be randomly selected to receive the drug or placebo at first. We are very excited to participate as one of several sites around the country. If you or someone you know is interested in taking part in KINECT-HD, please contact our study coordinator ZsaZsa Brown at 312-503-4121 or email zsazsa.brown@northwestern.edu. ​
 
Telemedicine for Huntington's Clinical Care 

Individuals with Huntington's disease are invited to participate in the study "TeleHD" to determine the feasibility and value of telemedicine visits for HD patients and their care partners. This research study is conducted by Dr. Danielle Larson and Dr. Danny Bega.

Who is Eligible?
  • Have a diagnosis of Huntington’s Disease
  • Ages 18 to 70
  • Have a computer, laptop, tablet or phone with a camera, microphone, and internet access
  • Fluent in English
     
What will you be asked to do?
  • Complete two telemedicine visits (by camera at home) in addition to your two regular in-person Huntington’s Clinic visits over a 6-9 month time period.
  • During the visits, a neurologic exam will be performed and you will complete two cognitive tests. The telemedicine visits will likely take less than 30 minutes.
  • After each clinic visit, you will be asked to record the time and travel burden of your visit. 
  • After all of the visits, you will be asked to complete a survey about your satisfaction with telemedicine visits.

Please e-mail research study assistant Robert Modiest at robert.jr3@northwestern.edu​ or call 312-503-5645 to let him know your interest, or if you have any questions. 

PROOF - HD: Coming in the next few months
Northwestern is excited to be participating in the PROOF-HD Study. This is a phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of an oral drug called Pridopidine in patients with early stage Huntington's disease. The objective is to see if Pridopidine can slow down functional decline in Huntington's disease when compared to a placebo pill. If you are interested in learning more about the study and how to get involved, please reach out to study coordinator ZsaZsa Brown at 312-503-4121.